文献速递头颈部肿瘤放疗姑息放疗与转移瘤

转移灶放疗对转移性鼻咽癌患者的疗效:一项多中心回顾性研究

Efficacy of metastatic lesion radiotherapy in patients with metastatic nasopharyngeal carcinoma: A multicenter retrospective study.
PubMed 文献 · Radiother Oncol · 2024-04-24

该多中心回顾性研究纳入1157例转移性鼻咽癌患者,采用倾向性评分匹配后比较接受与未接受转移灶放疗者的总生存。转移灶放疗组总生存显著优于未放疗组(原始队列28 vs 21个月,匹配队列26 vs 23个月),多因素分析显示转移灶放疗为总生存的独立有利预测因素(HR 0.67)。亚组分析提示放疗对肝、肺、骨转移有效,尤其转移负荷有限者;推荐转移灶放疗最小BED≥56 Gy。

要点

  • 转移灶放疗组总生存显著优于未放疗组:原始队列28 vs 21个月,匹配队列26 vs 23个月。
  • 多因素分析显示转移灶放疗为总生存的独立有利预测因素,HR 0.67。
  • 转移负荷有限者从转移灶放疗获益最大,推荐最小BED≥56 Gy。

核心结论

  • 转移灶放疗为转移性鼻咽癌患者提供生存优势。
  • 转移负荷有限的患者从转移灶放疗中获益最大。
  • 转移灶放疗的推荐方案为最小BED 56 Gy以获得最佳结局。

研究设计与样本

  • 多中心回顾性研究,纳入三家机构的转移性鼻咽癌患者1157例。
  • 采用倾向性评分匹配(PSM)确保组间可比性。
  • 采用Kaplan-Meier法评估总生存率,log-rank检验进行比较。
  • 采用单因素和多因素Cox风险分析识别预后因素,并进行亚组分析。

主要发现

  • 接受转移灶放疗的患者总生存显著优于未接受者:原始队列28 vs 21个月,PSM队列26 vs 23个月。
  • 多因素分析显示转移灶放疗为总生存的独立有利预测因素,HR 0.67。
  • 亚组分析提示放疗有效治疗肝、肺和骨转移灶,尤其在肿瘤负荷有限的患者中。
  • 较高的转移灶放疗总剂量(BED≥56 Gy)与总生存改善相关。
  • 放疗技术或剂量分割均未独立影响预后。

关键数值与推荐

  • 转移灶放疗推荐最小BED为56 Gy以获得最佳结局。

临床怎么用

  • 对转移性鼻咽癌患者可考虑转移灶放疗以改善总生存,尤其转移负荷有限者。
  • 转移灶放疗剂量建议达到最小BED 56 Gy。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: We investigated the efficacy of metastatic lesion radiotherapy (MLRT) in patients with metastatic nasopharyngeal carcinoma (mNPC). MATERIALS AND METHODS: Patients with mNPC from three institutions were included in this study. Propensity score matching (PSM) was employed to ensure comparability between patient groups. Overall survival (OS) rates were assessed using the Kaplan-Meier method and compared using the log-rank test. Prognostic factors were identified using univariate and multivariate Cox hazard analyses. Subgroup analyses were conducted to assess the effects of MLRT on specific patient populations. RESULTS: We analyzed data from 1157 patients with mNPC. Patients who received MLRT had significantly better OS than those who did not, both in the original (28 vs. 21 months) and PSM cohorts (26 vs. 23 months). MLRT was identified as an independent favorable predictor of OS in multivariate analyses, with hazard ratios of 0.67. The subgroup analysis results indicated that radiotherapy effectively treated liver, lung, and bone metastatic lesions, particularly in patients with a limited tumor burden. Higher total radiation doses of MLRT (biologically effective dose (BED) ≥ 56 Gy) were associated with improved OS, while neither radiation technique nor dose fractionation independently influenced prognosis. CONCLUSIONS: MLRT offers survival advantages to patients diagnosed with mNPC. Patients with limited metastatic burden derive the most benefit from MLRT, and the recommended regimen for MLRT is a minimum BED of 56 Gy for optimal outcomes.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Liu Y, Ma J, Zeng XY, et al. Efficacy of metastatic lesion radiotherapy in patients with metastatic nasopharyngeal carcinoma: A multicenter retrospective study. Radiother Oncol. 2024. PMID: 38670263. doi:10.1016/j.radonc.2024.110311

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。